Opinion|Videos|July 24, 2024
Ensuring PNH Treatment Access and Adherence to Therapies
Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What strategies can effectively ensure seamless access to therapies (eg, partnering with specialized pharmacies for dispensing)?
- When considering treatment options, how do factors related to supporting and enhancing adherence influence your choice of therapy? Could you discuss the opportunities and approaches you leverage to promote optimal treatment adherence in this patient population?
Advertisement
Related to this article
Pooled data on 2698 patients tie rituximab maintenance after bendamustine-rituximab to better PFS and OS in mantle cell lymphoma.
Pharmacists outline new oncologic therapeutics, from pancreatic cancer to myeloma, and what high prices and crowded markets mean for payers.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
Advertisement
Advertisement
Trending on AJMC
1
NYC Marathon Death Puts Rhabdomyolysis Risk Factors in Focus
2
Real-World Evidence, Rare Liver Disease Data Headline Kidney Week 2026
3
Acoramidis Linked to Fewer Hospitalizations Than Tafamidis in ATTR-CM
4
Disease Extent Linked to Complications After Deep Endometriosis Surgery
5